Director, Quantitative Clinical Pharmacology: PK/PD Modeling & Strategy
Sarepta Therapeutics
Summary
The Director of Quantitative & Clinical Pharmacology will be responsible to lead clinical pharmacology and pharmacometrics deliverables from early through late-stage clinical development (Ph3 and product registration), with an emphasis on clinical dose selection/refinement and predictive PK/PD modeling inclusive of population and statistically-based methodologies, as well as mechanistic and translational-focused approaches. This is a highly visible and team-facing role.
Job description
The Importance of the Role
The Director of Quantitative & Clinical Pharmacology will be responsible to lead clinical pharmacology and pharmacometrics deliverables from early through late-stage clinical development (Ph3 and product registration), with an emphasis on clinical dose selection/refinement and predictive PK/PD modeling inclusive of population and statistically-based methodologies, as well as mechanistic and translational-focused approaches. This is a highly visible and team-facing role.
The Opportunity to Make a Difference
- Drives the development and execution of the quantitative pharmacology strategies across all stages of drug development through product registration
- Leads clinical pharmacology expertise in clinical and translational development strategies, protocol preparation, study execution, data review/analysis, study reports
- Responsible for model-based data analyses including population PK, PK/PD modeling and simulation, meta-analysis, disease modeling to inform clinical development
- Serves as functional lead for global regulatory strategies and HA engagements
- Maintains leading-edge knowledge in clinical pharmacology and pharmacometrics discipline, publishes manuscripts, presents at scientific conferences and scientific forums
More about You
- PhD in Pharmaceutical Sciences, mathematics/engineering or related field with 7 years of experience working in clinical pharmacology or pharmacometrics
- Strong understanding of clinical pharmacology principles, strong hands-on experience with PK/PD modeling analysis, and experience in regulatory interactions
- Excellent communication, multitasking, and collaboration skills
- Experience in NONMEM & R highly preferred
- siRNA and/or CNS experience is preferred
Requirements
- PhD in Pharmaceutical Sciences, mathematics/engineering or related field
- 7 years of experience working in clinical pharmacology or pharmacometrics
- Strong understanding of clinical pharmacology principles
- Strong hands-on experience with PK/PD modeling analysis
- Experience in regulatory interactions
- Excellent communication, multitasking, and collaboration skills
- Experience in NONMEM & R highly preferred
- siRNA and/or CNS experience is preferred
- Candidates must be authorized to work in the U.S.
Benefits
- Physical and Emotional Wellness
- Financial Wellness
- Support for Caregivers
Company overview
Sarepta Therapeutics is a global biotechnology company headquartered in Cambridge, Massachusetts, focused on developing precision genetic medicines for rare diseases. Founded in 1980, the company has evolved into a commercial-stage biopharmaceutical leader with a specialized focus on RNA-based therapeutics and gene therapies. Sarepta's primary mission centers on treating devastating rare genetic disorders, particularly Duchenne muscular dystrophy (DMD), a progressive muscle-wasting disease affecting children. The company has developed multiple FDA-approved treatments including Exondys 51, Amondys 45, Vyondys 53, and the groundbreaking gene therapy ELEVIDYS. Sarepta employs approximately 1,300-1,400 professionals and maintains research facilities across multiple locations. The company's scientific platform leverages Morpholino oligomer technology for exon-skipping therapies and advanced adeno-associated virus (AAV) vectors for gene therapy delivery. With a market capitalization exceeding $2 billion, Sarepta continues to expand its pipeline to address additional rare diseases while building the world's largest gene therapy manufacturing capacity to accelerate patient access to transformative treatments.